Idexx LaboratoriesIDXXEarnings & Financial Report
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions.
IDXX Q3 2025 Key Financial Metrics
Revenue
$1.1B
Gross Profit
$683.4M
Operating Profit
$354.8M
Net Profit
$274.6M
Gross Margin
61.8%
Operating Margin
32.1%
Net Margin
24.8%
YoY Growth
13.3%
EPS
$3.40
Financial Flow
Idexx Laboratories Q3 2025 Financial Summary
Idexx Laboratories reported revenue of $1.1B for Q3 2025, with a net profit of $274.6M (24.8% margin). Cost of goods sold was $421.9M, operating expenses totaled $328.5M.
Key Financial Metrics
| Total Revenue | $1.1B |
|---|---|
| Net Profit | $274.6M |
| Gross Margin | 61.8% |
| Operating Margin | 32.1% |
| Report Period | Q3 2025 |
Idexx Laboratories Annual Revenue by Year
Idexx Laboratories annual revenue history includes year-by-year totals (for example, 2024 revenue was $3.9B).
| Year | Annual Revenue |
|---|---|
| 2024 | $3.9B |
| 2023 | $3.7B |
| 2022 | $3.4B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $901.6M | $964.1M | $1.00B | $975.5M | $954.3M | $998.4M | $1.11B | $1.11B |
| YoY Growth | 8.8% | 7.1% | 6.4% | 6.6% | 5.8% | 3.6% | 10.6% | 13.3% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.26B | $3.35B | $3.41B | $3.35B | $3.29B | $3.21B | $3.33B | $3.39B |
| Liabilities | $1.78B | $1.78B | $1.83B | $1.73B | $1.70B | $1.77B | $1.87B | $1.83B |
| Equity | $1.48B | $1.57B | $1.58B | $1.62B | $1.60B | $1.45B | $1.46B | $1.56B |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $249.9M | $198.6M | $248.3M | $220.1M | $262.0M | $238.0M | $185.7M | $402.3M |
Other Health Care Companies
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
BAX
Baxter International
Revenue
$3.0B
Net Profit
$-1.1B
BDX
Becton Dickinson
Revenue
$5.3B
Net Profit
$382.0M
BSX
Boston Scientific
Revenue
$5.3B
Net Profit
$670.0M
DXCM
Dexcom
Revenue
$1.3B
Net Profit
$267.3M
EW
Edwards Lifesciences
Revenue
$1.6B
Net Profit
$291.1M
GEHC
GE HealthCare
Revenue
$5.7B
Net Profit
$588.0M
HOLX
Hologic
Revenue
$1.0B
Net Profit
$179.1M
PODD
Insulet Corporation
Revenue
$783.7M
Net Profit
$101.6M
ISRG
Intuitive Surgical
Revenue
$2.9B
Net Profit
$794.8M